KNSA
Kiniksa Pharmaceuticals International, plc
$61.11
-0.58 (-0.94%)
At close · Jul 16
Market Cap
$9.40B
Shares
153,876,032
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-06-30 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-05-29 | — | |
| 8-K | 2026-05-26 | 2026-05-21 | |
| 8-K | 2026-05-01 | 2026-04-30 | |
| 10-Q | 2026-04-28 | 2026-03-31 | |
| 8-K | 2026-04-28 | — | |
| DEF 14A | 2026-04-16 | 2026-05-19 | |
| 10-K | 2026-02-24 | 2025-12-31 | |
| 8-K | 2026-02-24 | — | |
| 8-K | 2026-01-14 | 2026-01-10 | |
| 8-K | 2026-01-12 | — | |
| 10-Q | 2025-10-28 | 2025-09-30 | |
| 8-K | 2025-10-28 | — | |
| 8-K | 2025-09-03 | — | |
| 8-K | 2025-07-29 | — | |
| 10-Q | 2025-07-29 | 2025-06-30 | |
| 8-K | 2025-06-05 | — | |
| 8-K | 2025-06-03 | — | |
| 8-K | 2025-04-29 | — | |
| 10-Q | 2025-04-29 | 2025-03-31 | |
| 8-K | 2025-04-23 | 2025-04-17 | |
| DEF 14A | 2025-04-21 | 2025-06-03 | |
| 10-K | 2025-02-25 | 2024-12-31 | |
| 8-K | 2025-02-25 | 2025-02-21 | |
| 8-K | 2025-01-13 | — | |
| 10-Q | 2024-10-29 | 2024-09-30 | |
| 8-K | 2024-10-29 | — | |
| 8-K | 2024-10-07 | 2024-10-04 | |
| 10-Q | 2024-07-25 | 2024-06-30 | |
| 8-K | 2024-07-23 | — | |
| 8-K | 2024-06-25 | — | |
| 8-K | 2024-06-14 | — | |
| 8-K | 2024-06-05 | — | |
| 10-Q | 2024-04-25 | 2024-03-31 | |
| 8-K | 2024-04-23 | — | |
| DEF 14A | 2024-04-23 | 2024-06-05 | |
| 8-K | 2024-04-02 | — | |
| 8-K | 2024-03-29 | — | |
| 10-K | 2024-02-28 | 2023-12-31 | |
| 8-K | 2024-02-28 | — | |
| 8-K | 2024-01-04 | — | |
| 10-Q | 2023-11-02 | 2023-09-30 | |
| 8-K | 2023-10-31 | — | |
| 10-Q | 2023-08-01 | 2023-06-30 | |
| 8-K | 2023-07-25 | — | |
| 8-K | 2023-06-07 | 2023-06-06 | |
| 10-Q | 2023-05-04 | 2023-03-31 | |
| 8-K | 2023-05-02 | — | |
| DEF 14A | 2023-04-27 | 2023-06-06 |
Showing 1–50 of 101 filings
Key facts
CIK
1730430
CUSIP
G52694109
13F (30d)
15 filings
14 filers
Visit website
Investor relations